A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Paget's Disease of Bone Clinical Trial

Official title:
A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone

Status Completed

Clinical Trial Summary

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00480662
Study type	Interventional
Source	Organon and Co
Contact
Status	Completed
Phase	Phase 3
Start date	October 2001
Completion date	October 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00747994` - Genetic Study of Families Affected by Paget's Disease of Bone	N/A
Completed	`NCT00774020` - Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)	Phase 4
Completed	`NCT00051636` - Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period	Phase 3
Completed	`NCT00306046` - 18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone	N/A
Active, not recruiting	`NCT02802384` - Pathophysiology of Paget's Disease of Bone
Completed	`NCT00103740` - Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period	Phase 3